A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
A phase 2/3 trial of Vebreltinib run by Beijing Pearl Biotechnology Limited Liability Company, active.
Overview
A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). is a phase 2/3 interventional study registered as NCT06105619 by Beijing Pearl Biotechnology Limited Liability Company, with 84 participants enrolled, started 2018-10-08. Conditions listed: Glioblastoma. No results are recorded here; the registry entry is the source.
Setting
A Randomized, Controlled, Open, Multicenter, Phase II/III Clinical Study to Evaluate the Safety and Efficacy of Vebreltinib Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
Phase
Phase 2/3
Sponsor
Beijing Pearl Biotechnology Limited Liability Company
Registry
Enrolled
84